Dopamine, hypertension and obesity

Abstract

Dopamine (DA), a neurotransmitter, precursor of noradrenaline, is responsible for cardiovascular and renal actions, such as increase in myocardial contractility and cardiac output, without changes in heart rate, producing passive and active vasodilatation, diuresis and natriuresis. These cardiovascular and renal actions take place through the interaction with dopamine receptors, D 1, D 2, D 3, D 4, and D 5. Recent findings point to the possibility of D 6 and D 7 receptors. Dopamine is known to influence the control of arterial pressure by influencing the central and peripheral nervous system and target organs such as kidneys and adrenal glands, in some types of hypertension. Although dopamine and its derivatives have been shown to have antihypertensive effects, these are still being studied; therefore it is important to explain some physiological and pharmacological aspects of dopamine, its receptors and the clinical uses that could have in the treatment of Arterial Hypertension (AHT), and more recently in obesity, based on evidences proving a clear association between obesity and the decrease in the expression of D 2 receptors in the brain of obese persons.